Medtronic enters stent fray with Endeavor

Share this article:
Medtronic's Endeavor stent
Medtronic's Endeavor stent
Medtronic won approval for its Endeavor drug-eluting stent Friday, making it the third player in a market likely to get much more competitive.

The company bills the device as a next-generation stent meeting significant unmet patient need “by providing the effectiveness of a drug-eluting stent but with a safety profile more commonly associated with a bare metal stent.”

In November, Johnson & Johnson's Cordis launched the category's first broadcast DTC, with its “Life Wide Open” TV, print and online campaign plugging its Cypher stent. J&J and Taxus maker Boston Scientific have long split the market, which has been buffeted by mixed data on the safety and efficacy of coated stents. More recent studies have backed the utility of the stents, and with Abbott seeking approval for its Xience stent, a scramble for market share should soon be underway.

Yesterday, Boston Scientific reported a $458 million loss for the fourth quarter amid continued torpor in the market for coated stents and several big-ticket charges. The firm's stock nonetheless closed up 3.9% for the day, suggesting that Wall Street has hope for stronger stent sales ahead.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...